Pleased to share our latest work, published today in @ESMO_Open 👇 As HER-targeted ADCs continue to evolve, understanding HER1–HER4 co-expression may help inform future drug development and patient selection. sciencedirect.com/science/ar… @OncoAlert 🧵Key findings:

Important review on EV+P toxicities from colleagues @MayoCancerCare. Causal attributions are incredibly challenging due to patient heterogeneity & the many overlapping toxicities between EV and P. Great read for oncologists who treat multiple cancers since SOC EV+P use is currently limited to MIBC and la/mUC. @OncoAlert @DrKarineTawagi @LauraBukavinaMD @IBCG_BladderCA @BladderCancerUS

Quite a surprise, I-dxd BLA application withdrawn. The wait for an ADC for small cell lung cancer outside China will continue, disappointing news #lcsm stocktitan.net/news/MRK/ifin…

The eternal question in solid tumor oncology, almost Shakespearean in its persistence When is Cisplatin better than Carbo? When are they equivalent? Excited to share our new paper in @JAMANetworkOpen where we examined the certainty of evidence of the 11 major meta-analyses (12 683 pts) on which guidelines based their recommendations ✴️Several efficacy variables have low or very low level of certainty ✳️Only high-certainty evidence signal was found for Cis>Carbo in ORR urothelial, and the no PFS difference Cis=Carbo in ovarian. 🟡Despite high heterogeneity impacting GRADE across tumour types, toxicities show known correlations The story does not end here, highlighting the utility of meta-data appraisals and current evidence gaps. We might not need new trials, just greater access to data from completed studies #oncology @myESMO @ASCO 👏An honour to have worked with and learned from this faculty Prof Harrington @MattGalsky Prof Colombo @EnriquetaFelip Dr Rodon @juditsanz Dr Pereira @DrMirallas @OncoAlert @brunolarvol @OncBrothers

What if a missed cancer diagnosis could cost you 8 years of life? 🚨 On this #WeekinOncology #Melanoma by OncoAlert🚨, our #OncoAlertAF colleagues Dr. Mario Balsa 🇪🇸 discusses an article out on Nature communications and how a melanoma study reveals the devastating long-term impact of false-negative diagnoses—and why getting the diagnosis right the first time matters. Would a 2-year diagnostic delay change the outcome? nature.com/articles/s41467-0… A large German 🇩🇪 study of 9,063 melanoma patients found that an initially false-negative cancer diagnosis can have serious long-term consequences. Among 206 patients with a missed diagnosis, the median delay to correct diagnosis was 24 months. Their 10-year recurrence-free and melanoma-specific survival were significantly lower than those diagnosed correctly. ✅️ Most strikingly, an initial false-negative diagnosis was associated with an average loss of 8.2 years of life, highlighting the critical importance of accurate and timely cancer detection. @TeresaSAmaral, @PAscierto, @JeffGershenwald, @jmkirkwood, @CelesteLebbe, @ProfGLongMIA, @jasonlukemd, @DWhitemanQIMRB, @pdnpdnpdn, @SaraGandini3 📣 Pinging our faculty: @nataliagandur, @realbowtiedoc, @FernandoOnco, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @BRicciutiMD, @HHorinouchi, @UOzkerim, @p_ciracimd, @AmandaNizamMD, @scocmem, @DrVilmaPBarcia, @DraMartinezLago, @DrMirallas, @GIMedOnc, @BettinaRyll 🎗️ Pinging our colleagues in melanoma: @DrBetofMDPhD, @FunchainMD, @CureMelanoma, @Melanoma_doctor, @HTawbi_MDPhD, @Chrystal_Paulos, @JaniceM10, @ProfGLongMIA, @ProfRAScolyer, @JeffGershenwald, @MelanomaAus, @AIMatMelanoma

🚨 FDA Priority Review granted for durvalumab plus neoadjuvant enfortumab vedotin in muscle-invasive #BladderCancer : VOLGA Update Source: AstraZeneca The submission is supported by Phase III VOLGA results showing statistically significant and clinically meaningful improvements in event-free survival and overall survival. @DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @AlbigesL, @cdanicas, @amerseburger, @sonpavde, @DrDanielHeng, @declangmurphy, @seanmmcbride, @HHammersMD, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @scocmem, @ravikanesvaran, @AmandaNizamMD, @drenriquegrande, @BraunMDPhD, @EfstathiouEleni, @nataliagandur, @crisbergerot, @realbowtiedoc, @FernandoOnco, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @BRicciutiMD, @HHorinouchi, @UOzkerim, @p_ciracimd, @DrMirallas

FDA grants Priority Review for the VOLGA trail, in which 3 neoadjuvant cycles of EV and a year of Perioperative durvalumab was given for patients with muscle invasive bladder cancer. Press release states an EFS and OS advantage. Data will be presented #ESMO26 @OncoAlert @myESMO @Annals_Oncology astrazeneca-us.com/content/a…

Priority review by the @FDA for neoadjuvant EV+Durvalumab based on #VOLGA study which is not yet presented!, but soon at #ESMO26 Interesting—and somewhat unusual—to see a Priority Review announcement with a PDUFA action date already in Q4 2026. The perioperative bladder cancer space is moving very fast. #bladdercancer #GUonc @OncoAlert @DanaFarber_GU @myESMO @AstraZeneca @AstraZenecaUS @OncoBellmunt @tompowles1 astrazeneca-us.com/content/a…

📢 The FDA has approved belzutifan + lenvatinib for advanced RCC with a clear cell component after PD-1/PD-L1 therapy. Based on LITESPARK-011 (PFS HR 0.74; ORR 53% vs 40%; OS HR 0.85 not significant), the first positive phase 3 vs TKI post-ICI. @OncoAlert fda.gov/drugs/resources-info…

We need a dedicated adjuvant UTUC trial with an ADC-IO combo comparing to platinum/IO. We are working on getting it started with @eaonc soon! @PGrivasMDPhD @MonikaJoshimd @MattGalsky @DrRosenbergMSK

Check out this commentary by @VivekSubbiah 👇🏼 Terms like “triple-negative”, “wild-type” or “non-small cell” feel more outdated as we move beyond the microscope and our understanding of cancer biology and therapeutics evolves. @Annals_Oncology @OncoAlert annalsofoncology.org/article…

Europe's biggest cancer conference, ESMO, is coming soon! The 'late-breaking abstracts' at the plenary are the biggest clinical trials to be presented - here are the details on all 12:

🆕October issue now online 👉Thymic radiation associated with worse outcomes in NSCLC 👉Final outcomes of the SOFT and TEXT phase III trials 👉Becotatug vedotin for recurrent/metastatic nasopharyngeal carcinoma (Magic-M001) Read this issue: annalsofoncology.org/issue/S…

📣 #ESMO26: The late-breaking abstract lineup is taking shape! Authors & titles are online, and most of the submissions are already there. 30K+ delegates already registered from around the world, so this means new data, new insights and new opportunities to connect. Register now! 🔗 ow.ly/hRv350ZQ7ZW

🫵🫵Beyond clinical staging in UTUC? Combined utDNA + plasma ctDNA predicted muscle-invasive disease (OR 8.5; p=.004), improving specificity (70% vs 25%) and accuracy (76% vs 54%) over clinical risk assessment,while maintaining 81% sensitivity pubmed.ncbi.nlm.nih.gov/4276… @OncoAlert

Interesting data on liquid biopsy in localised UTUC 👇🏼 – utDNA was ⬆️⬆️ sensitive with 94-95% genomic concordance with the primary UTUC –Urine could also inform ctDNA testing with similar performance to tumour-informed ctDNA @OncoAlert euoncology.europeanurology.c…

🚨Hot off the press 👉Pleased to share an editorial "The rare cancer ‘zebra’ advantage: flipping the script for success in oncology drug development" @myESMO Rare Cancers journal @ESMO_Open @OncoAlert @oncodaily - read the 🧵 @X torial 1/8 esmorarecancers.org/article/…

This week's OncoAlert 🚨 Newsletter is packed with practice-changing data: REGISTER TO GET IT 👉 buff.ly/N5gYtAc Pinging: @OncoAlert, @Uromigos, @matteolambe, @aftimosp, @E_de_Azambuja, @DrSGraff, @ErikaHamilton9, @double_whammied, @maryam_lustberg, @raalbany, @hoperugo, @stolaney1, @LoiSher, @JaniceTNBCmets, @montypal, @DrDanielHeng, @apolo_andrea, @DrChoueiri, @PGrivasMDPhD, @TiansterZhang, @neerajaiims, @amerseburger, @sonpavde, @drenriquegrande, @tompowles1, @cdanicas, @nataliagandur, @realbowtiedoc, @Onco_Cifu88, @scocmem, @FernandoOnco, @ElisaAgostinett, @to_be_elizabeth, @Erman_Akkus, @MarioBalsaMD, @DrMirallas, @GIMedOnc, @UOzkerim, @DrRishabhOnco, @PaulJiL, @DaisukeKotani, @DraMartinezLago, @p_ciracimd, @BenWestphalen, @CentralParkWMD, @graokane, @amandaNizamMD, @DrVilmaPBarcia → Tambotatug pelitecan nearly doubled response rates over topotecan in relapsed small-cell lung cancer — 59.1% vs 9.7% — with fewer grade ≥3 events (NEJM) → 8-year ADAURA follow-up: adjuvant osimertinib holds a durable overall-survival benefit in resected EGFR-mutated NSCLC — 79% vs 64% at 8 years (JTO) → 2026 EAU guidelines update the playbook for relapsing and metastatic prostate cancer — PARP inhibitors, PSMA-based treatment, and more (European Urology) → Reduced-dose leucovorin (200 mg/m²) matched full-dose outcomes in metastatic colorectal cancer — a practical fix for ongoing shortages (ASCO Global Oncology) And much much more

I wonder how you would treat a patient after nephro-uretectomy for a high grade, T3N0M0 upper tract urothelial cancer. The tumor is PD-L1+ve and ctDNA-ve. The pateint is not eligible for cisplatin. @DrChoueiri @montypal @PGrivasMDPhD @OncoAlert @Annals_Oncology

ADCs account for almost one-quarter of the LBAs at #ESMO26! (23%, for a more quantitative perspective)

Fantastic to join this amazing group of #ESMOAmbassadors #ESMO26 @myESMO covering many updates, highlights, insights! @StephenVLiu @aftimosp @PTarantinoMD @rachnatshroff @g_mountzios @Ecastromarcos @VivekSubbiah @DrAngelaLamarca @ErikaHamilton9 @marinagarassino @GPentheroudakis